Publication: 2113

N083E (Alliance): Long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
      QxMD      Google Scholar   
Citation:
Breast Cancer Res Treat vol 182 (3) 613-622
Year:
2020
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
9
Parents:
417  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10 CA035103, UG1 CA189808, UG1 CA189812, U10 CA035415, U10 CA063849  
Corr. Author:
 
Authors:
                         
Networks:
FL028, LAPS-MN026, MVCC, NICRC, PR028   
Study
NCCTG-N083E
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Breast cancer, HER2 cardiac, Gastrointestinal, Tolerability, Lapatinib, Adjuvant